These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 3511284)

  • 21. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.
    Kelley DR; Haaff EO; Becich M; Lage J; Bauer WC; Dresner SM; Catalona WJ; Ratliff TL
    J Urol; 1986 Feb; 135(2):268-71. PubMed ID: 3511285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Sarosdy MF; Lamm DL
    J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
    Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM
    J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
    Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
    Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
    Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
    Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL
    J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
    Okuno H; Shirahase T; Kihara Y; Arai Y
    Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
    Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
    J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management.
    Herr HW; Whitmore WF
    J Urol; 1987 Aug; 138(2):292-4. PubMed ID: 3599241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local bacillus Calmette-Guerin therapy for superficial bladder cancer: clinical, histological and ultrastructural patterns.
    Rigatti P; Colombo R; Montorsi F; Centemero A; Guazzoni G; Di Girolamo V; Galli L; Trabucchi E
    Scand J Urol Nephrol; 1990; 24(3):191-8. PubMed ID: 2237295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
    Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
    J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
    Eure GR; Cundiff MR; Schellhammer PF
    J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.